Aqualung Therapeutics Concludes ALT-100 Antibody Dosing in Its P1a Study with no Reported SAEs. Will Engage FDA for Clearance of the P2a PUERTA Study in ModerateSevere Acute Respiratory Distress Syndrome Patients
ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Slightly above 55% of Aridis Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Aridis Pharmaceuticals pink sheet suggests that some investors are interested at this time. Aridis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Aridis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Aridis Pharmaceuticals pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Aridis daily returns and investor perception about the current price of Aridis Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Aridis |
Aqualung has selected Novotech as their CRO partner to conduct the P2a PUERTA study in moderatesevere ARDS subjects.Expected screening for enrolled subjects to begin AprilMay 2023.Aqualung Submitting an end of P1 meeting data packet to the FDA in February based on preliminary results of the P1a Healthy Human Volunteer study.TUCSON, AZ ACESSWIRE January 31, 2023 Aqualung Therapeutics, an early stage immunotherapeutics company with a
Read at finance.yahoo.com
Aridis Pharmaceuticals Fundamental Analysis
We analyze Aridis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aridis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aridis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Aridis Pharmaceuticals is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Aridis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aridis Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aridis Pharmaceuticals Related Equities
RVPH | Reviva Pharmaceuticals | 8.77 | ||||
AKTX | Akari Therapeutics | 8.04 | ||||
ADTX | Aditxt | 5.71 | ||||
ATXI | Avenue Therapeutics | 4.37 | ||||
ABVC | ABVC Biopharma | 3.92 | ||||
RNAZ | Transcode Therapeutics | 2.94 | ||||
DRMA | Dermata Therapeutics | 2.73 | ||||
KOD | Kodiak Sciences | 1.83 | ||||
UNCY | Unicycive Therapeutics | 1.47 | ||||
REVB | Revelation Biosciences | 1.33 | ||||
HOTH | Hoth Therapeutics | 1.20 | ||||
NRBO | Neurobo Pharmaceuticals | 0.43 | ||||
CGTX | Cognition Therapeutics | 2.44 | ||||
ZVSA | ZyVersa Therapeutics | 3.60 | ||||
RVPHW | Reviva Pharmaceuticals | 4.35 | ||||
VRAX | Virax Biolabs | 4.83 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |